JP2019517549A - Ｃ−ｒａｆ阻害薬の治療的使用 - Google Patents

Ｃ−ｒａｆ阻害薬の治療的使用 Download PDF

Info

Publication number
JP2019517549A
JP2019517549A JP2018564296A JP2018564296A JP2019517549A JP 2019517549 A JP2019517549 A JP 2019517549A JP 2018564296 A JP2018564296 A JP 2018564296A JP 2018564296 A JP2018564296 A JP 2018564296A JP 2019517549 A JP2019517549 A JP 2019517549A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018564296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517549A5 (cg-RX-API-DMAC7.html
Inventor
カポニグロ，ジョルダーノ
クック，ヴェセリーナ
ヘレナ マイス，アンナ
ヘレナ マイス，アンナ
ノウェラーツ，ハイディ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019517549A publication Critical patent/JP2019517549A/ja
Publication of JP2019517549A5 publication Critical patent/JP2019517549A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018564296A 2016-06-10 2017-06-08 Ｃ−ｒａｆ阻害薬の治療的使用 Pending JP2019517549A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348720P 2016-06-10 2016-06-10
US62/348,720 2016-06-10
PCT/IB2017/053405 WO2017212442A1 (en) 2016-06-10 2017-06-08 Therapeutic uses of a c-raf inhibitor

Publications (2)

Publication Number Publication Date
JP2019517549A true JP2019517549A (ja) 2019-06-24
JP2019517549A5 JP2019517549A5 (cg-RX-API-DMAC7.html) 2020-07-16

Family

ID=59215827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564296A Pending JP2019517549A (ja) 2016-06-10 2017-06-08 Ｃ−ｒａｆ阻害薬の治療的使用

Country Status (13)

Country Link
US (1) US20190175609A1 (cg-RX-API-DMAC7.html)
EP (1) EP3468595A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019517549A (cg-RX-API-DMAC7.html)
KR (1) KR20190017767A (cg-RX-API-DMAC7.html)
CN (1) CN109310761A (cg-RX-API-DMAC7.html)
AU (1) AU2017279046B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018075371A2 (cg-RX-API-DMAC7.html)
CA (1) CA3026876A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003530A1 (cg-RX-API-DMAC7.html)
IL (1) IL262961A (cg-RX-API-DMAC7.html)
MX (1) MX2018015353A (cg-RX-API-DMAC7.html)
RU (1) RU2018146886A (cg-RX-API-DMAC7.html)
WO (1) WO2017212442A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550219A (ja) * 2019-12-06 2022-11-30 メッドシャイン ディスカバリー インコーポレイテッド Ｐａｎ－ＲＡＦキナーゼ阻害剤としてのビアリール化合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3515446B1 (en) * 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
DK3618875T3 (da) 2017-05-02 2023-07-10 Novartis Ag Kombinationsterapi omfattende en raf-inhibitor og trametinib
US10945904B2 (en) 2019-03-08 2021-03-16 Auris Health, Inc. Tilt mechanisms for medical systems and applications
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
CN113912591B (zh) * 2020-07-08 2023-10-20 齐鲁制药有限公司 联芳基化合物
WO2022253334A1 (zh) * 2021-06-04 2022-12-08 南京明德新药研发有限公司 一种raf激酶抑制剂的晶型及其制备方法
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252977A1 (en) * 2012-03-07 2013-09-26 Deciphera Pharmaceuticals, Llc Raf Inhibitor Compounds
WO2014151616A1 (en) * 2013-03-14 2014-09-25 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015112800A1 (en) * 2014-01-23 2015-07-30 Regeneron Pharmaceuticals, Inc. Human antibodies to pd-1
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3102605T (pt) * 2014-02-04 2019-02-12 Pfizer Combinação de um antagonista da mp-1 e um inibidor do rfcev para o tratamento do cancro
WO2016011160A1 (en) * 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252977A1 (en) * 2012-03-07 2013-09-26 Deciphera Pharmaceuticals, Llc Raf Inhibitor Compounds
WO2014151616A1 (en) * 2013-03-14 2014-09-25 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015112800A1 (en) * 2014-01-23 2015-07-30 Regeneron Pharmaceuticals, Inc. Human antibodies to pd-1
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAT. REV. DRUG DISCOV., 2014, VOL.13, NO.11, PP.828-851, JPN6021020965, ISSN: 0004925256 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550219A (ja) * 2019-12-06 2022-11-30 メッドシャイン ディスカバリー インコーポレイテッド Ｐａｎ－ＲＡＦキナーゼ阻害剤としてのビアリール化合物
JP7214925B2 (ja) 2019-12-06 2023-01-30 メッドシャイン ディスカバリー インコーポレイテッド Ｐａｎ－ＲＡＦキナーゼ阻害剤としてのビアリール化合物

Also Published As

Publication number Publication date
MX2018015353A (es) 2019-09-09
US20190175609A1 (en) 2019-06-13
KR20190017767A (ko) 2019-02-20
RU2018146886A3 (cg-RX-API-DMAC7.html) 2020-10-15
RU2018146886A (ru) 2020-07-10
AU2017279046B2 (en) 2020-07-02
AU2017279046A1 (en) 2018-12-06
EP3468595A1 (en) 2019-04-17
CN109310761A (zh) 2019-02-05
IL262961A (en) 2018-12-31
WO2017212442A1 (en) 2017-12-14
BR112018075371A2 (pt) 2019-03-19
CA3026876A1 (en) 2017-12-14
CL2018003530A1 (es) 2019-02-15

Similar Documents

Publication Publication Date Title
JP2019517549A (ja) Ｃ−ｒａｆ阻害薬の治療的使用
CN108025051B (zh) 包含抗pd-1抗体分子的联合疗法
US20180177872A1 (en) Combination of PD-1 antagonist with an EGFR inhibitor
JP2019516712A (ja) 癌を処置するためのグルタミン酸調節剤と免疫療法の併用
JP2024012300A (ja) 医薬併用
WO2023240082A2 (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
AU2021378793B2 (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
JP2022547550A (ja) Ｐｄ－１軸阻害剤及び抗ペリオスチン抗体の使用により癌を処置する方法。
JP2024527334A (ja) 抗ｏｘ４０モノクローナル抗体及びその使用方法
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
KR20190107719A (ko) 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정
RU2788092C2 (ru) Молекулы антител к pd-1 и их применения
WO2020044252A1 (en) Dosage regimes for anti-m-csf antibodies and uses thereof
JP2019218346A (ja) がんの処置に使用するための５−ブロモ−２，６−ジ−（１ｈ−ピラゾール−１−イル）ピリミジン−４−アミン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221122